|
发表于 2007-7-4 06:54:56
|
显示全部楼层
来自: 美国
<h2>A case of lung adenocarcinoma of the lung with disappearance of brain
metastasis by re-treatment with gefitinib</h2>
<p class="MsoNormal" style="margin-bottom: 12pt;">[Article in Japanese]</p>
<p class="MsoNormal"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Kato%20T%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus"><b>Kato
T</b></a>, <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Nakashima%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus"><b>Nakashima
M</b></a>, <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Yoshimura%20K%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus"><b>Yoshimura
K</b></a>, <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Imao%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus"><b>Imao
M</b></a>, <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Goto%20H%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus"><b>Goto
H</b></a>, <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Yasuda%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus"><b>Yasuda
S</b></a>, <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sano%20K%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus"><b>Sano
K</b></a>.</p>
<p class="affiliation">Respirtory Medicine, <st1place><st1placename>National</st1placename>
<st1placetype>Hospital</st1placetype>
<st1placename>Nagara</st1placename>
<st1placename>Medical</st1placename>
<st1placetype>Center</st1placetype></st1place>.</p>
<p class="abstract">BACKGROUND: Tumor response rate to gefitinib by previously
treated patients with advanced non-small-cell lung cancer was approximately
20%. However, there are few reports about effect of re-treatment with gefitinib.
CASE: A 40-year-old man was given a diagnosis of adenocarcinoma of lung
(c-T2N3M1). Response was not obtained with chemotherapy (paclitaxel +
carboplatin, vinorelbine + gencitabin). He developed brain metastasis and
received whole brain radiation therapy. He was then given gefitinib. Reduction
of the primary tumor, brain metastasis, pulmonary metastasis and liver
metastasis was seen. Recurrence of pulmonary metastasis and liver metastasis
was discovered 8 months after treatment with gefitinib. Therefore, treatment by
gefitinib was stopped. Response was not achieved with chemotherapy (docetaxel
and amrubicin). At the request of the patient, retreatment with gefitinib was
resumed. Disappearance of brain metastasis was achieved. However, primary tumor,
pulmonary metastasis and liver metastasis progressed. CONCLUSION: We reported a
case whose brain metastases disappeared with re-treatment with gefitinib. This
report is thought to be useful in terms of information about the acquired
resistance of gefitinib. Further investigations are needed to determine the
indication of re-treatment with gefitinib.</p>
<p class="MsoNormal"><span style="font-family: "MS Mincho";">一</span>
<span style="font-family: "MS Mincho";">例肺腺癌并</span><span style="font-family: PMingLiU;">发脑转移, 重用IRESSA后</span><span style="font-family: PMingLiU;">脑转移</span><span style="font-family: PMingLiU;">完全消失的例子<op></op></span></p>
<p class="MsoNormal">[<span style="font-family: "MS Mincho";">原文</span><span style="font-family: MingLiU;">为</span><span style="font-family: "MS Mincho";">日文</span>] </p>
<p class="MsoNormal"><span style="font-family: "MS Mincho";">加藤 T</span>,<span>  </span>Nakashima M, <span style="font-family: "MS Mincho";">等</span><op></op></p>
<p class="MsoNormal"><span style="font-family: PMingLiU;">国家医院长良医疗中心,
呼吸医学<op></op></span></p>
<p class="MsoNormal">.<span style="font-family: "MS Mincho";">背景</span>:</p>
<p class="MsoNormal"><span style="font-family: PMingLiU;">对以往已治疗过晚期非小细胞肺癌肿瘤,IRESSA反应率为约占</span>20%
. <span style="font-family: "MS Mincho";">但是</span>,
<span style="font-family: "MS Mincho";">只有少数重用IRESSA的</span><span style="font-family: PMingLiU;">报道</span>. </p>
<p class="MsoNormal"><span style="font-family: "MS Mincho";">案例</span>:</p>
<p class="MsoNormal"><span style="font-family: "MS Mincho";">一个</span>40<span style="font-family: PMingLiU;">岁男子被诊断为肺腺癌</span>(<span style="font-family: "MS Mincho";">C</span>- t2n3m1 ) <span style="font-family: PMingLiU;">化疗没有取得效果</span> (<span style="font-family: "MS Mincho";">紫杉醇</span>+<span style="font-family: "MS Mincho";">卡</span><span style="font-family: PMingLiU;">铂</span>,<span style="font-family: PMingLiU;">诺维</span>gencitabin
+ ) . <span style="font-family: "MS Mincho";">他</span><span style="font-family: MingLiU;">发</span><span style="font-family: "MS Mincho";">展了</span><span style="font-family: PMingLiU;">脑转移,接受全脑放射治疗</span>.
<span style="font-family: "MS Mincho";">于是</span>,<span style="font-family: "MS Mincho";">他被</span><span style="font-family: PMingLiU;">给IRESSA治疗</span>.<span style="font-family: "MS Mincho";">原</span><span style="font-family: PMingLiU;">发性肿瘤</span>,<span style="font-family: PMingLiU;">脑转移</span>,<span style="font-family: "MS Mincho";">肺</span><span style="font-family: PMingLiU;">转移和肝转移</span>.<span style="font-family: "MS Mincho";">减少。</span>8<span style="font-family: "MS Mincho";">个月治</span><span style="font-family: PMingLiU;">疗后,发现肺转移和肝转移复发</span>.
<span style="font-family: "MS Mincho";">因此</span>,
<span style="font-family: "MS Mincho";">停止</span>IRESSA<span style="font-family: "MS Mincho";">治</span><span style="font-family: PMingLiU;">疗</span>. <span style="font-family: "MS Mincho";">后来的</span><span style="font-family: PMingLiU;">化疗</span>(<span style="font-family: "MS Mincho";">紫杉醇</span>amrubicin
)<span style="font-family: "MS Mincho";">
</span><span style="font-family: PMingLiU;">未取得效果</span> . <span style="font-family: "MS Mincho";">在病人提出要求下</span>,<span style="font-family: "MS Mincho";">IRESSA被恢</span><span style="font-family: PMingLiU;">复</span>.<span style="font-family: PMingLiU;">脑转移达到完全消失</span>. <span style="font-family: "MS Mincho";">然而</span>,<span style="font-family: "MS Mincho";">原</span><span style="font-family: PMingLiU;">发性肿瘤</span>,<span style="font-family: "MS Mincho";">肺</span><span style="font-family: PMingLiU;">转移和肝转移进展</span>.</p>
<p class="MsoNormal"><span> </span><span style="font-family: PMingLiU;">结论</span>:</p>
<p class="MsoNormal"><span style="font-family: "MS Mincho";">本病例中,重用IRESSA后的</span><span style="font-family: PMingLiU;">脑转移瘤消失</span>,. <span style="font-family: PMingLiU;">这份报告被认为是有用的信息,当IRESSA获得抗药性</span>. <span style="font-family: PMingLiU;">进一步调查后才能确定重用IRESSA的作用范围。</span>.
</p> |
|